Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
XRP Critic Peter Brandt Says Stellar (XLM) Is a Good Pick for Long Shot Bet. Here’s why

XRP Critic Peter Brandt Says Stellar (XLM) Is a Good Pick for Long Shot Bet. Here’s why

TimesTabloidTimesTabloid2026/09/29 11:03

Veteran trader Peter Brandt recently dropped a major prediction for Stellar (XLM). “If you want to bet on a long shot (next few years), XLM is a good pick,” he wrote. The post offered both a price target and a chart structure to support that view.

The Chart Structure

The monthly chart covers XLM’s price history from 2018 through late 2026. A declining upper trendline connects each successive cycle high, with peaks moving lower over time. The 2018 high reached $0.9381. The 2021 high came in near $0.75. The 2025 high reached approximately $0.65. Each rally failed at a lower level than the previous.

Below the price action, a rising trendline has held as support across the same multi-year period. The asset’s price has returned to that level repeatedly and held. XLM currently sits at $0.23041, near that long-term support line. Brandt is convinced that the long-term trajectory is bullish.

Indicators and Moving Averages

The chart displays two moving averages. The 18-period average sits at $0.23041, and the 8-period average sits at $0.18827. Price is trading between those two levels. The ADX reads 33.91, indicating trend strength. The 30-period Average True Range is $0.1075, reflecting significant volatility on the monthly timeframe.

A Recurring Cycle

Brandt previously identified constructive technical structure in XLM, describing the asset as one that “could become a rock star.” That earlier analysis noted a rising support base and long-term resistance that had capped the asset since 2018.

The chart labels two prior lows as “SH” and “S,” visible near the 2019-2020 base. That base preceded the 2021 rally that took XLM above $0.70. The current price sits in a comparable zone near long-term support. Each of the three major rallies on the chart originated from a similar position.

The Price Target of His Multi-Year Thesis

Brandt has marked a price target of $1.17605 on the chart. It appears as a horizontal green line. Reaching that level from the current price would require about a 410% rally. Brandt’s post suggests this is not a short-term trade. He also set a long-term target for XRP. His analysis is grounded in technical patterns and data.

Brandt has included XLM among a small group of assets he views constructively alongside Bitcoin, XRP, and Ethereum. His latest post extends that view with a defined upside target and a timeframe measured in years.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53